{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:47:07Z","timestamp":1765961227075,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.gore.2020.100552","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:04:30Z","timestamp":1582250670000},"page":"100552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Megan","family":"Lander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-1919","authenticated-orcid":false,"given":"Yasmin","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5649-4319","authenticated-orcid":false,"given":"Sofia","family":"Gabrilovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna Z.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gore.2020.100552_b0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gore.2020.100552_b0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2020.100552_b0015","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.gore.2020.100552_b0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.gore.2020.100552_b0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3892\/mco.2016.1107","article-title":"Paclitaxel and platinum-based chemotherapy results in transient dyslipidemia in cancer patients","volume":"6","author":"Wang","year":"2017","journal-title":"Mol. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2020.100552_b0030","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jacl.2018.07.005","article-title":"The clinical importance of recognizing capecitabine-induced hypertriglyceridemia: A case report and review of the literature","volume":"12","author":"Leung","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.gore.2020.100552_b0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/1078155214532508","article-title":"Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature","volume":"21","author":"Han","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"2","key":"10.1016\/j.gore.2020.100552_b0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1590\/2359-3997000000068","article-title":"PEG-asparaginase induced severe hypertriglyceridemia","volume":"60","author":"Galindo","year":"2016","journal-title":"Arch. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.gore.2020.100552_b0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0936-6555(98)80019-8","article-title":"Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use","volume":"10","author":"Colls","year":"1998","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.gore.2020.100552_b0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer","year":"2014","journal-title":"J. Clin. Gastroenterol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:55:47Z","timestamp":1762480547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578920300187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":10,"alternative-id":["S2352578920300187"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2020.100552","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2020.100552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100552"}}